Page 1

● ● PRESS RELEASE Immatics Announces First Quarter 2021 Financial Results and Business Update Data update for ongoing ACTengine® IMA200 clinical trial series demonstrated first anti tumor activity in heavily pre - treated solid cancer patients during early phases of dose escalation ● immatics Next ACTengine® data update for dose levels 2 and 3 on track for H2 2021 Preclinical proof - of - concept for second TCR Bispecifics ( TCER® ) program IMA402 against the frequently expressed cancer target PRAME announced Cash and cash equivalents as well as other financial assets of $ 254.0 million ( € 216.7 million¹ ) as of March 31 , 2021 provide cash reach into 2023 Tuebingen , Germany and Houston , TX , May 18 , 2021 Immatics N.V. ( NASDAQ : IMTX ; " Immatics " ) , a clinical - stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies , today reported financial results and provided a business update for the quarter ended March 31 , 2021 . First Quarter 2021 and Subsequent Company Progress " In the first quarter of 2021 , we reported first anti - tumor activity at the initial dose levels of our ACTengine® IMA200 clinical trial series which indicates the potential of our engineered Adoptive Cell Therapy approach . We continue to scale up enrollment by initiating additional trial sites in the US and Europe - and now look forward to treating patients at target dose levels and provide a next update in the second half of 2021 , " said Harpreet Singh , Ph.D. , CEO of Immatics . “ In addition , we are on track with our first clinical trial application for TCER® towards the end of this year . By engaging two therapeutic modalities , Adoptive Cell Therapy and TCR Bispecifics , we are aiming to address a broad cancer patient population with an urgent need for new therapeutic options . " - Immatics Press Release May 18 , 2021 Adoptive Cell Therapy Programs ACTengine® IMA200 series - Immatics provided a clinical data update from three ongoing ACTengine® Phase 1 trials for its engineered Adoptive Cell Therapy approach ( also known as TCR - T ) in March . The combined data readout during early phases of dose escalation for the ACTengine® programs , IMA201 , IMA202 and IMA203 , indicated first anti - tumor activity with tumor shrinkage observed in 8 out of 10 patients including one unconfirmed partial response as of data cut - off . This was consistent with the observed robust engraftment , persistence and tumor infiltration of infused ACTengine® T cells . Overall , the product candidates demonstrated a manageable safety and tolerability profile . 1 | 10